Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $160 from $169 and keeps a Neutral rating on the shares. The firm The firm updated its model following its mixed Q4 report. New products are driving the 2025 outlook which with upside possible if markets rebound.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOVT: